We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$83M
AUM Growth
-$44.6M
Cap. Flow
-$70.3M
Cap. Flow %
-84.78%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$38.2M
2
VYGR icon
Voyager Therapeutics
VYGR
+$17.8M
3
FULC icon
Fulcrum Therapeutics
FULC
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
1
Pliant Therapeutics
PLRX
$65M
$48.9M 58.97%
1,839,160
– –
VYGR icon
2
Voyager Therapeutics
VYGR
$189M
$24.6M 29.6%
3,185,291
-2,243,642
-41% -$17.8M
DBTX
3
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$9.48M 11.43%
3,139,685
– –
FULC icon
4
Fulcrum Therapeutics
FULC
$283M
– –
-1,962,202
Closed -$14.3M
RVMD icon
5
Revolution Medicines
RVMD
$41.8B
– –
-1,604,130
Closed -$38.2M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q1 2023 Portfolio in Review

As of Q1 2023, TRV GP III held 5 positions worth $83M, down 35% from $128M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $70.3M in Q1 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Revolution Medicines, an estimated $38.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q1 2023 reduction was Voyager Therapeutics, cutting an estimated $17.8M.
  • TRV GP III fully exited Revolution Medicines in Q1 2023, selling an estimated $38.2M.
  • TRV GP III's ten largest holdings make up 100% of its $83M portfolio in Q1 2023.
  • TRV GP III opened 0 new positions and closed 2 in Q1 2023.
  • TRV GP III's portfolio value fell 35% quarter-over-quarter to $83M.

Based on TRV GP III's 13F filing for Q1 2023, filed 12 May 2023.